Pro-inflammatory (IL-6, TNF␣ and IL-8) and antiinflammatory (IL-10) cytokines were determined in weekly samples from 52 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). IL-6 increased immediately after transplant peaking at week +3, but IL-8 concentrations were elevated only during week +1. After a slight decrease in week +1, TNF-␣ significantly increased from week +2 and peaked at week +3, whereas, IL-10 values started to rise in week +2 and peaked during week +4. IL-6 and TNF-␣ were positively correlated from week +2 to week +4, and IL-6 levels at week +1 were related with fever and severe stomatitis. Serum levels of IL-6 at week +1 and IL-10 at week +4 were significantly higher in patients with early transplant-related complications, such as fever, severe stomatitis or acute GVHD у overall grade II than in those without the complications. We conclude that a high serum IL-6 level at week +1 may be an early predictor of transplant-related complications and that it seems to trigger pro-and anti-inflammatory cytokine release. Kinetic patterns of IL-6 and IL-10 were more exaggerated in those with complications after HSCT. Bone Marrow Transplantation (2001) 28, 935-940.
kine production may initiate and perpetuate tissue damage in those receiving bone marrow and solid organ transplantation. 1 Interleukin (IL)-6, tumor necrosis factor (TNF)-␣, and IL-8 are well known pro-inflammatory cytokines, which are involved in local and systemic inflammatory reactions. These cytokines have been found to be involved in many adverse conditions initiated by HSCT. [2] [3] [4] [5] [6] IL-10 is a Th2 cytokine that inhibits cytokine production by Th1 cells, and IL-10 is reported to block the production of the monokines (IL-1, IL-6 and TNF-␣) in response to lipopolysaccharide or other stimuli. 7, 8 High spontaneous IL-10 production in transplant recipients is associated with fewer transplantrelated complications, and is believed to have a major role in maintaining immunobalance in the allogeneic HSCT setting. 9, 10 The levels of IL-6, TNF-␣ and IL-8 in serum after HSCT have been reported by many groups, but little attention has been paid to their correlation with IL-10. In order to identify a diagnostic parameter for the prediction of early clinical complications and to define their role in the pathogenesis, we studied the relationship between the serum concentrations of pro-and anti-inflammatory cytokines and transplantation-related complications in a series of 52 patients undergoing allogeneic HSCT.
Material and methods

Patients and transplant characteristics
Fifty-two allogeneic HSCT patients were continuously enrolled in our institute; 19 had chronic myelogenous leukemia (CML), 18 acute myelogenous leukemia (AML), eight acute lymphocytic leukemia (ALL), four severe aplastic anemia (SAA) and three had refractory anemia with excess blasts in transformation (RAEBT), as shown in Table 1 . Eight patients received bone marrow (BM) from human leukocyte antigen (HLA)-matched unrelated donors and two patients from one-locus mismatched related donors at the HLA-B or the -DR loci. Thirty patients (57.7%) received total body irradiation (TBI) as a conditioning regimen. All the patients received 300-450 g of granulocyte colony-stimulating factor (G-CSF) from day +7 until the absolute neutrophil count exceeded 3.0 × 10 9 /l.
GVHD prophylaxis and treatment
For GVHD prophylaxis, 41 patients (78.8%) received a combination of cyclosporin A (CsA) and methotrexate (MTX). CsA was administered i.v. at a dose of 3 mg/kg as a continuous infusion from days −1 to +21. Thereafter CsA was given orally at 5 mg/kg/day divided into two doses, to maintain a blood concentration between 200 and 500 ng/ml. MTX was administered at 10 mg/m 2 on days +1, +3, +6 and +11. FK-506 and MTX were used for GVHD prophylaxis in 11 patients (21.2%). FK-506 was given i.v. at a dose of 0.03 mg/kg as a continuous infusion from days −1 to +21 and orally at 0.12 mg/kg/day divided into two doses, to maintain a blood concentration between 10 and 30 ng/ml. 11 Acute GVHD was based on clinical signs and graded on a four-point scale (I indicated mild disease, and IV severe disease). 12 Methylprednisolone 4 mg/kg/day for 4-7 days with gradual taper was used to treat acute GVHD уgrade II.
Complications after HSCT
Complications observed in this group of patients included: (1) acute GVHD уgrade II, diagnosed on clinical findings; (2) fever of unknown origin, defined as fever у38.3°C for at least 2 consecutive days; (3) oral mucositis уgrade III, scored in accordance with the NCI criteria; (4) 
Blood sample collection and the cytokine level determination
In order to measure the biochemical markers and cytokines, venous blood samples were taken between 7 am and 9 am following an overnight fast, aseptically in tubes containing EDTA and sodium citrate. Following centrifugation for 10 min, aliquots of serum were stored at −20°C until analysis. In all patients, blood was sampled before the conditioning and at 1, 2, 3 and 4 weeks and 3 months after the transplant. IL-6, TNF-␣, IL-8 and IL-10 were measured in duplicate using a sandwich ELISA kit (Hyundae Pharm. Institute, Incheon, Korea). Detection limits were 4, 8, 10 and 10.4 pg/ml, respectively. The maximum inter-and intraassay CV for the range of concentrations evaluated were: 8.3% and 6.2% for IL-6; 8.2% and 7.0% for TNF-␣; 7.4% and 7.6% for IL-8; and 9.8% and 5.6% for IL-10, respectively. In order to investigate the possibility of a correlation with renal or hepatic function, serum total bilirubin (TB), creatinine (Cr) and lactic dehydrogenase (LDH) levels were determined using an autoanalyser (747 Automatic Analyser, Hitachi, Japan).
Statistical analysis
Wilcoxon's signed rank test was used to analyze the cytokine profiles in matched pairs during the pre-and posttransplant period. The Mann-Whitney U test or the Moses test was used to compare cytokine profiles according to the occurrence of complications. Correlations between numerical variables were assessed using the Spearman rank test. Differences were considered statistically significant when P Ͻ 0.05.
Results
Cytokine levels during the early course of HSCT
IL-6 levels increased significantly from week +1 to week +4 after HSCT compared with pre-transplant levels (mean ± s.e.m.: baseline, 36.9 ± 8.6 pg/ml; 1st week, 105.7 ± 15.9 pg/ml, P Ͻ 0.001; 2nd week, 142.5 ± 26.2 pg/ml, P Ͻ 0.001; 3rd week, 159.8 ± 29.0 pg/ml, P Ͻ 0.001; 4th week, 148.3 ± 19.2 pg/ml, P = 0.002). The IL-6 level on week +12 (mean ± s.e.m.: 113.4 ± 21.6 pg/ml) was not significantly different from the pretransplant level (P = 0.061). After a slight decrease on week +1, TNF-␣ increased from week +2 to week +3 (mean ± s.e.m.: baseline; 67.2 ± 16. pg/ml; 2nd week 94.1 ± 13.2 pg/ml, P Ͻ 0.001; 3rd week, 145.6 ± 23.7 pg/ml, P Ͻ 0.001) and then decreased from week +4 (118.61 ± 15.54 pg/ml vs baseline, P = 0.001). However, the mean ± s.e.m. at week +12 after HSCT remained higher than the pretransplant level (107.3 ± 14.4 pg/ml, P = 0.013). IL-8 levels were elevated at week +1 compared with the baseline concentrations (mean ± s.e.m.: 18.42 ± 2.06 vs 15.49 ± 3.01 pg/ml, P = 0.011) but did not show any significant change after the 2nd week. IL-10 levels increased between weeks +2 and +4 (mean ± s.e.m.: baseline; 13.2 ± 1.5 pg/ml; 2nd week, 28.6 ± 2.2 pg/ml, P Ͻ 0.001; 3rd week, 41.9 ± 3.7 pg/ml, P Ͻ 0.001; 4th week, 46.5 ± 4.5 pg/ml, P = 0.008) and returned to the pre-transplant level on week +12 post HSCT (10.1 ± 0.8 pg/ml, P = 0.69) (Figure 1 ).
IL-6 at week +1 correlated significantly with IL-6 at week +2 (r = 0.559, P Ͻ 0.001). The levels of IL-6 at week +2 correlated strongly with those of TNF-␣ at week +2 (r = 0.506, P Ͻ 0.001), week +3 (r = 0.522, P Ͻ 0.001) and week +4 (r = 0 .447, P = 0.042). IL-6 and IL-8 or IL-10 concentrations were positively correlated at week +2, and TNF-␣ with IL-8 at week +3 (Table 2) . TNF-␣ (week +2) concentrations correlated with IL-6 (week +3) (r = 0.463, P = 0.001). Similarly, TNF-␣ (week +3) was correlated with IL-6 (week +4) (r = 0.538, P = 0.014). Weeks after transplant Weeks after transplant Cytokine concentrations in fever, mucositis, and acute GVHD IL-6 levels at week +1 were significantly higher in patients with fever (n = 11) or stomatitis (n = 9), which occurred between days +1 and +10, than in uncomplicated patients (n = 28) (mean ± s.e.m.: 203.4 ± 25.7 pg/ml vs 73.9 ± 8.2 pg/ml, P = 0.01 for fever; 239.3 ± 26.6 pg/ml vs 73.9 ± 8.2 pg/ml, P = 0.002 for stomatitis). IL-6 elevations at week +1 observed during acute GVHD уgrade II tended to be elevated (mean ± s.e.m.; 130.1 ± 50.7 pg/ml vs 73.9 ± 13.8 pg/ml, P = 0.309). With the exception of IL-6 at week +1, no statistically significant differences were observed in the levels of the other cytokines at set times with respect to the occurrence of fever, stomatitis, or acute GVHD.
The increases in IL-6, TNF-␣, and IL-10 were not due to early complications after HSCT, since patients with uncomplicated courses (n = 28) showed a pattern similar to those with complications (n = 24). However, the serum concentrations of IL-6 and IL-10 in patients with complications were significantly higher at weeks +1 and +4, respectively, than in those without complications (Figure 2) .
Relationship between cytokine concentrations and serum bilirubin, creatinine and LDH values
Some positive correlations were observed between the serum bilirubin/creatinine/LDH values and the cytokine levels. IL-6 and creatinine levels correlated positively at week +4 (r = 0.543, P = 0.011), and IL-10 correlated positively with LDH at week +1 (r = 0.495, P = 0.019) and with creatinine at week +4 (r = 0.783, P = 0.013). Although the correlation was not observed on the same days, the elevated levels of several cytokines seemed to be related to renal or hepatic dysfunction (Table 3) . Weeks after transplant Weeks after transplant 
Relationship between serum cytokine levels and basal disease or different types of transplant
Underlying disease did not have an important effect on cytokine profiles. Serum IL-10 levels at week +1 were slightly higher in patients with advanced disease than those with early stage (23.9 ± 7.8 pg/ml vs 12.6 ± 2.8 pg/ml, P = 0.059). No differences in the serum levels of IL-6, TNF-␣ or IL-10 were detected, according to the type of transplant or conditioning regimen. Baseline IL-8 levels in patients receiving transplant from alternative donors were significantly higher than in those receiving a matched sibling transplantation (18.7 ± 6.1 pg/ml vs 14.7 ± 5.8 pg/ml, P = 0.0018), but there were no differences after transplant.
Discussion
Cytokine levels in sera from 52 patients who had undergone allogeneic HSCT were sequentially measured to characterize their behavior between the aplastic phase and through the marrow recovery phase, and to evaluate their involvement in the case of early complications, such as fever, stomatitis and acute GVHD. In the present study, we tried to identify the key cytokines involved in the pathomechanism of complications after allogeneic HSCT. In particular, the kinetics of circulating IL-10 release after allogeneic HSCT in comparison with other cytokines, such as TNF-␣, IL-6, and IL-8 was investigated.
We examined the interactions of pro-inflammatory and anti-inflammatory cytokines at the same time. Our results suggest that IL-6 production could be readily activated by allogeneic HSCT per se and that IL-10 levels peak sometime later in rivalry with the production of pro-inflammatory cytokines. The kinetic patterns of IL-6 and IL-10, observed during the early phase of HSCT, were found to be different in those patients with early complications and those without. In our patients who developed complications, IL-6 and IL-10 concentrations were significantly higher at weeks +1 and +4, respectively, compared to the uncomplicated patients, which suggests a more exaggerated pattern of kinetics in those with complications after HSCT.
Our data also showed that IL-6 seemed to be the most important cytokine during the initial inflammatory process, as it was the first cytokine to increase (in week +1). A detailed comparison of cytokine serum concentrations including pro-or anti-inflammatory effects showed a very high variability that hindered further analysis. 5, 6, 15 Most of the cytokines are produced by specific cell types in response to specific stimuli. In contrast, IL-6 is produced by almost all cells, including hepatocytes, in response to any type of stimulation. 4, 5, 16 Therefore, it is unusual not to find increased IL-6 levels in human pathological conditions. In our patients, IL-6 levels correlated significantly with those of the other cytokines, particularly TNF-␣ ( Table 2) . The experimental data demonstrated that TNF-␣ is up to 100-fold more potent with regard to IL-10 induction than any other cytokines. 17 Consequently, elevated levels of IL-6 at week +1 may be associated with IL-10 at week +4, throughout a network of cytokines, and have an influence on the occurrence of early complications. The emerging Bone Marrow Transplantation recognition that the shift from a Th1 to Th2 can downregulate cell-mediated immune response and the inflammatory process should intensify research concerning the role of these regulatory cytokines during the course of complications.
Within the cytokine network, the activation of proinflammatory mediators is followed by increased production of endogenous inhibitory molecules including the antagonistic cytokines. The serum IL-10 concentration is correlated with the production of inflammatory cytokines such as IFN␥, IL-1, IL-6 and TNF-␣. 7, 8 Indeed, systemic TNF-␣ release during pre-transplant conditioning, which was previously reported to be an indicator of poor outcome, was inhibited in patients with high IL-10 production. 9, 10, 18 However, Hempel et al 19 reported that high IL-10 serum levels in patients after HSCT were significantly associated with a fatal outcome. In the present study, the difference between IL-10 concentrations at week +4 in patients with early complications and those without was remarkable (P Ͻ 0.001). It is possible that IL-10 could be produced by activated monocytes rather by T cells, and increased macrophage activation has been observed at the time of engraftment. 20 Immunosuppressive therapy with glucocorticoid, which constitutes the mainstay of acute GVHD therapy, could also have contributed to the cytokine kinetics. In our patients (n = 24) with early complications, only 10 patients with acute GVHD received steroid treatment, and IL-10 levels were not different in complicated patients who received steroid and those who did not (data not shown). It is unlikely that the marked increase of IL-10 levels in our patients in week +4 was caused by engraftment or steroid, and it is more likely that, in those with complications, the IL-10 levels increased in week +4 mainly as a consequence of pro-inflammatory cytokine activation.
Imamura et al 4 reported that acute GVHD appeared to be induced by the synergistic interaction of IL-6, IFN␥ and TNF-␣, which is consistent with a cytokine cascade. Our results did not show such an association between serum cytokine concentrations and the occurrence of acute GVHD уgrade II. IL-6 levels in those with acute GVHD were not significantly different from those without, although these levels were slightly higher in patients with acute GVHD. Less striking correlation between acute GVHD and IL-6 may be due to the small sample size of patients with acute GVHD уgrade II (n = 10). Moreover, in some cases, even though IL-6 and TNF-␣ increased no GVHD developed (data not shown). We reaffirmed that IL-6 correlates with both a raised body temperature and with severe oral mucositis. IL-8 plays a major role in the modulation of inflammatory responses, including GVHD or severe VOD. 3, 21 In addition, IL-8 is abundantly produced by normal hepatocytes, and endothelial injury occurring in the liver during VOD may elevate systemic IL-8 concentrations. 3 In our patients, no positive correlation between IL-8 and GVHD was observed and only one patient developed severe VOD 14 of the liver. However, we did find a positive correlation between each cytokine and bilirubin, LDH and creatinine concentrations. Similar findings concerning IL-6 and hepatic or renal function have been reported upon previously. 2, 22 In summary, IL-10 reached a peak concentration a little later after transplant than IL-6 and TNF-␣. Of the cytokines studied (IL-6, TNF-␣, IL-8 and IL-10) only IL-6 and IL-10 were found to have kinetic patterns that correlated with early complications, such as fever, severe stomatitis and acute GVHD. We believe that serum IL-6 levels may be an early predictor of transplant-related complications and may trigger pro-and anti-inflammatory cytokine release.
